A 52 WEEK, PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH PRIMARY HYPERLIPDEMIA OR MIXED DYSLIPIDEMIA AT RISK OF CARDIOVASCULAR EVENTS. SPIRE-LL: STUDIES OF PCSK9 INHIBITION AND THE REDUCTION OF VASCULAR EVENTS - LIPID LOWERING
- Registry ID
- B1481045
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- PFIZER CANADA INC
- Start date
- 2014-11-20
- Last update
- 2014-10-10
Conditions
- MIXED DYSLIPIDEMIA
- PRIMARY HYPERLIPIDEMIA
Related clinical trials
- A DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED, MULTICENTER STUDY TO EVALUATE SAFETY, TOLERABILITY, AND EFFICACY ON LDL-C OF EVOLOCUMAB (AMG 145) IN SUBJECTS WITH HIV AND WITH HYPERLIPIDEMIA AND/OR MIXED DYSLIPIDEMIN
- A PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH PRIMARY HYPERLIPIDEMIA OR DYSLIPDEMIA AT RISK OF CARDIOVASCULAR EVENTS
- "A MULTICENTER, CONTROLLED, OPEN-LABEL EXTENSION (OLE) STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF AMG 145."
View on source registry